Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adcetris plus ESHAP in relapsed or refractory classical Hodgkin lymphoma
NCT02243436Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Nov 2014
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by GELTAMO. Started Nov 2014; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT02243436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243436.